Salvat Laboratories has submitted a new drug application to the FDA for clobetasol nanoemulsion to treat inflammation and pain after ocular surgery.
The application is supported by two phase 3 clinical trials that demonstrated positive efficacy and safety results for the corticosteroid in more than 400 patients. In addition, there was a low impact on IOP in the clinical trials, according to a press release.
The therapy demonstrated no rebound effects in the 2 weeks after a standard 14-day course of treatment, with no requirement for a gradual decrease in (Read more...)